Management of pulmonary hypertension in left heart disease.

about

Left ventricular dysfunction in patients with suspected pulmonary arterial hypertension.

P2860

Q34993093-8C83D07D-28E0-4772-9150-FB2F03453CFE

P2860

Management of pulmonary hypertension in left heart disease.

Item

http://www.wikidata.org/entity/Q38099630

description

article científic

@ca

article scientifique

@fr

articol științific

@ro

articolo scientifico

@it

artigo científico

@gl

artigo científico

@pt

artigo científico

@pt-br

artikel ilmiah

@id

artikull shkencor

@sq

artículo científico

@es

name

Management of pulmonary hypertension in left heart disease.

@en

type

Item

label

Management of pulmonary hypertension in left heart disease.

@en

prefLabel

Management of pulmonary hypertension in left heart disease.

@en

P1476

Management of pulmonary hypertension in left heart disease.

@en

P2093

Alexander Schmeisser

http://www.w3.org/2001/XMLSchema#string

Hagen Schroetter

http://www.w3.org/2001/XMLSchema#string

Ruediger C Braun-Dulleaus

http://www.w3.org/2001/XMLSchema#string

P2860

Canadian Cardiovascular Society Consensus Conference guidelines on heart failure, update 2009: diagnosis and management of right-sided heart failure, myocarditis, device therapy and recent important clinical trials

ACC/AHA 2006 guidelines for the management of patients with valvular heart disease: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (writing committee to revise the 1998 Guidelines for the

Right ventricular function in cardiovascular disease, part II: pathophysiology, clinical importance, and management of right ventricular failure

2008 focused update incorporated into the ACC/AHA 2006 guidelines for the management of patients with valvular heart disease: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Commit

Phosphodiesterase type 5 is highly expressed in the hypertrophied human right ventricle, and acute inhibition of phosphodiesterase type 5 improves contractility

Clinical classification of pulmonary hypertension.

Guidelines for heart transplantation.

Ventricular phosphodiesterase-5 expression is increased in patients with advanced heart failure and contributes to adverse ventricular remodeling after myocardial infarction in mice.

The influence of basal nitric oxide activity on pulmonary vascular resistance in patients with congestive heart failure.

Left ventricular assist devices decrease fixed pulmonary hypertension in cardiac transplant candidates.

P304

131-151

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1177/1753944713477518

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2013-04-16T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

23592742

http://www.w3.org/2001/XMLSchema#string

Management of pulmonary hypertension in left heart disease.

about

P2860

P2860

Management of pulmonary hypertension in left heart disease.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P577

P698

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P577

P698